F
Fabiënne A. R. M. Warmerdam
Publications - 10
Citations - 731
Fabiënne A. R. M. Warmerdam is an academic researcher. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 6, co-authored 7 publications receiving 443 citations.
Papers
More filters
Journal ArticleDOI
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats,Edwin P.M. Jansen,Nicole C.T. van Grieken,Karolina Sikorska,Pehr Lind,Marianne Nordsmark,Elma Meershoek-Klein Kranenbarg,Henk Boot,Anouk K. Trip,HA A. Maurits Swellengrebel,Hanneke W. M. van Laarhoven,Hein Putter,Johanna W. van Sandick,Mark I. van Berge Henegouwen,Henk H. Hartgrink,Harm van Tinteren,Cornelis J.H. van de Velde,Marcel Verheij,Frits van Coevorden,Steven Vanhoutvin,Maarten C.C.M. Hulshof,Olaf Jl Loosveld,A (Bert) Jan Ten Tije,Frans L. G. Erdkamp,Fabiënne A. R. M. Warmerdam,Donald L. van der Peet,Henk M.W. Verheul,Djamila Boerma,Maartje Los,Annerie Slot,Danny Houtsma,Johanna E.A. Portielje,Reinoud J. B. Blaisse,Ernst Jan Spillenaar Bilgen,Marco B Polée,Maud M. Geenen,Jeffrey P.B.M. Braak,Karen J. Neelis,Marije Slingerland,Rob L. H. Jansen,Jeroen Buijsen,Aart Beeker,Quirijn A. J. Eijsbouts,Johanna Mgh Van Riel,Tom Rozema,Dick Johan van Spronsen,Jetske M. Meerum Terwogt,Bea C Tanis,Adelheid Me Van der Torren-Conze,Richard Van Hilligersberg,Miriam Koopman,Marien O Den Boer,Geert-Jan Creemers,Maurice J.C. van der Sangen,Marjolein Em Rentinck,H Pieter van den Berg,Ge Jpm Jonkers,Diane Grootenboers,Annelie Je Vulink,Sjoerd Hovenga,Huub van der Mijle,Arnold Baars,A. Haringhuizen,Marije Ie Appels,Ron C Rietbroek,Ellen M Hendriksen,Marie-Cecile Jc Legdeur,Daan Ten Bokkel Huinink,O Aart Van Dobbenburgh,Jitty M Smit,Aart Van Bochove,Gerrit-Jan Veldhuis,Erik W Muller,Johannes J. Bonenkamp,Pètra M Braam,Jaap De Boer,Henk K Van Halteren,Fransje Aa Valster,Alex L. T. Imholz,Marjan A Van Dijk,Ate van der Gaast,J (Hans)-Martin Mb Otten,Heleen M. Ceha,Bengt Glimelius,Cecillia Lagerbäck,Mats Perman,Anders Johnsson,David Borg,Niels H Nielsen,Andrzej Piwowar,Mattias Elmlund,Helene Hörberg,Per Edlund,Bengt Johansson,Petra Flygare,Marie Louise Jespersen +95 more
TL;DR: This investigator-initiated, open-label, randomised phase 3 trial aimed to compare perioperative chemotherapy with preoperative chemotherapy and postoperative chemoradiotherapy in patients with resectable gastric adenocarcinoma.
Journal ArticleDOI
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
Bo Jan Noordman,Manon C.W. Spaander,Roelf Valkema,Bas P. L. Wijnhoven,Mark I. van Berge Henegouwen,Joel Shapiro,Katharina Biermann,Ate van der Gaast,Richard van Hillegersberg,Maarten C.C.M. Hulshof,Kausilia K. Krishnadath,Sjoerd M. Lagarde,Grard A. P. Nieuwenhuijzen,Liekele E. Oostenbrug,Peter D. Siersema,Peter D. Siersema,Erik J. Schoon,Meindert N. Sosef,Ewout W. Steyerberg,Ewout W. Steyerberg,J. Jan B. van Lanschot,Michael Doukas,Nanda C. Krak,Jan-Werner Poley,Caroline M. van Rij,Jaques Jghm Bergman,Suzanne S. Gisbertz,Hanneke W. M. van Laarhoven,Sybren L. Meijer,Lucas Goense,Nadia Haj Mohammad,Monique G.G. Hobbelink,G. Johan A. Offerhaus,Frank P. Vleggaar,Wouter L. Curvers,Geert-Jan Creemers,Mark J. Roef,Maurice J.C. van der Sangen,Jeroen Buijsen,Robert G. Riedl,Wendy M. J. Schreurs,Fabiënne A. R. M. Warmerdam,Mjr Janssen,Chella Van Der Post,Sandra A Radema,Camiel Rosman,H.J.T. Rutten +46 more
TL;DR: The correlation between clinical response during clinical response evaluations and the final pathological response in resection specimens was shown, as shown by the proportion of tumour regression grade (TRG) 3 or 4 residual tumours that was missed duringclinical response evaluations.
Journal ArticleDOI
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
Alessandro Leal,Nicole C.T. van Grieken,Doreen N. Palsgrove,Jillian Phallen,Jamie E. Medina,Carolyn Hruban,Mark A. M. Broeckaert,Valsamo Anagnostou,Vilmos Adleff,Daniel C. Bruhm,Jenna Van Liere Canzoniero,Jacob Fiksel,Marianne Nordsmark,Fabiënne A. R. M. Warmerdam,Henk M.W. Verheul,Dick Johan van Spronsen,Laurens V. Beerepoot,Maud M. Geenen,Johanneke E.A. Portielje,Edwin P.M. Jansen,Johanna W. van Sandick,Elma Meershoek – Klein Kranenbarg,Hanneke W. M. van Laarhoven,Donald L. van der Peet,Cornelis J.H. van de Velde,Marcel Verheij,Remond J.A. Fijneman,Robert B. Scharpf,Gerrit A. Meijer,Annemieke Cats,Victor E. Velculescu +30 more
TL;DR: In gastric cancer, the authors show that circulating tumour DNA can predict recurrence, provided that the signal from white blood cells is filtered out, and provide a facile method for distinguishing ctDNA from other cfDNA alterations.
Journal ArticleDOI
A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Ruben T. H. M. Larue,Lien Van De Voorde,Maaike Berbee,Wouter van Elmpt,Ludwig Dubois,Kranthi M. Panth,S. Peeters,S. Peeters,Ann Claessens,Wendy M. J. Schreurs,Marius Nap,Fabiënne A. R. M. Warmerdam,Frans L. G. Erdkamp,Meindert N. Sosef,Philippe Lambin +14 more
TL;DR: This is the first clinical trial testing evofosfamide in combination with chemoradiotherapy, and the primary objective is to determine the dose limiting toxicity of this combined treatment and to define the maximum tolerated dose and recommended phase 2 dose for future clinical studies.
Journal ArticleDOI
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.
Sushil K Badrising,Vincent van der Noort,Alfons J.M. van den Eertwegh,Paul Hamberg,Inge M. van Oort,Hendrik van den Berg,Maartje Los,Maureen J.B. Aarts,Jules L.L.M. Coenen,Hans Gelderblom,Igle J. de Jong,Emile D. Kerver,Suzan Vrijaldenhoven,Theo van Voorthuizen,Fabiënne A. R. M. Warmerdam,John B. A. G. Haanen,Andries M. Bergman +16 more
TL;DR: Abiraterone Acetate and Enzalutamide are effective hormonal treatments in mCRPC patients but only 12.8–39.1% of patients previously treated with docetaxel (Doc) and AA do respond to Enz.